Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Sandy Sargis
Advertisement
Sandy Sargis is a senior research associate in early-stage purification at Genentech, Inc.
Articles by Sandy Sargis
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
3
Welcome to CPHI Frankfurt 2025
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
